Bleichmar Fonti & Auld LLP Files Lawsuit Against Hims & Hers Health Executives.

A securities law firm, Bleichmar Fonti & Auld LLP, has filed a lawsuit against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws. Investors who purchased Hims & Hers securities are encouraged to visit the firm's website for more information. A lead plaintiff must be appointed by August 25, 2025, in the U.S. District Court for the Northern District of California.

NEW YORK, July 02, 2025 — Leading securities law firm Bleichmar Fonti & Auld LLP has filed a lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) and its senior executives for potential violations of federal securities laws. Investors who purchased Hims & Hers securities are encouraged to visit the firm's website for more information.

The lawsuit, filed in the U.S. District Court for the Northern District of California, alleges that Hims & Hers made false statements and concealed material information regarding its collaboration with Novo Nordisk. Specifically, the complaint asserts that Hims & Hers misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide to its customers. It is also alleged that Hims & Hers represented to investors that its sale of compounded semaglutide complied with FDA regulations, which was not the case [1].

On June 23, 2025, Novo Nordisk announced the termination of the partnership due to Hims & Hers' alleged deceptive promotion and selling of illegitimate, knockoff versions of Wegovy, which put patient safety at risk. This revelation led to a significant drop in Hims & Hers' stock price, declining by more than 34% from $64.22 to $41.98 per share [1].

Investors who suffered losses during the relevant time frame are urged to contact Bleichmar Fonti & Auld LLP by August 25, 2025, to request the appointment of a lead plaintiff. The firm will represent investors on a contingency fee basis, with no out-of-pocket costs or expenses [1].

Bleichmar Fonti & Auld LLP is a leading international law firm with a track record of representing plaintiffs in securities class actions and shareholder litigation. The firm has recovered over $900 million in value from Tesla, Inc. and $420 million from Teva Pharmaceutical Ind. Ltd. [1].

References:
[1] https://www.globenewswire.com/news-release/2025/07/08/3111773/0/en/HIMS-NOTICE-Hims-Hers-Health-Inc-Shareholders-are-Notified-of-the-Pending-Class-Action-Lawsuit-Contact-BFA-Law-by-August-25-Court-Deadline-NYSE-HIMS.html